If you have hesitated to consider hormone therapy because you heard it causes breast cancer or heart attacks, you are far from alone. That belief traces back to a single press conference in July 2002, and it has shaped how a generation of women and their doctors think about menopause. The science has moved a long way since then. This article explains what that study found, what two decades of follow-up research have clarified, who benefits most from hormone therapy, and who should avoid it.

What Happened in 2002

The Women’s Health Initiative was a large federally funded trial designed to test whether hormone therapy prevented heart disease in older women. In 2002, one arm of the study was stopped early after investigators reported increased risks of breast cancer, heart attack, stroke, and blood clots in women taking hormones compared with placebo. The headlines were dramatic, prescriptions for hormone therapy fell by more than half within a year, and many women stopped treatment abruptly [1].

What the headlines left out mattered. The women in the study had an average age of 63, and most were more than ten years past menopause; many already had cardiovascular risk factors. The medication was a specific combination: oral conjugated equine estrogens (derived from horse urine) and a synthetic progestin called medroxyprogesterone acetate. And the absolute increase in breast cancer risk, while real for that combination, amounted to fewer than one additional case per thousand women per year [1].

What Later Analysis Showed

Over the following two decades, researchers reanalyzed the WHI data by age and time since menopause and published long-term follow-up. Several findings changed the picture:

• Timing matters. Women who started hormone therapy under age 60 or within ten years of menopause did not show the increase in heart disease seen in older women; several analyses suggested a reduction in coronary disease and overall mortality in this younger group. This is now called the “timing hypothesis” and is central to current guidelines [2, 5].
• Estrogen alone looked different. In the WHI arm for women without a uterus, who took estrogen without a progestin, breast cancer risk was lower than placebo, not higher, in long-term follow-up [3, 4].
• The progestin was a key variable. The breast cancer signal in the combined arm is attributed largely to the synthetic progestin. Observational studies of micronized bioidentical progesterone have not shown the same increase, at least in the first several years of use [6].
• Route of estrogen matters for clots. Oral estrogen passes through the liver and increases clotting factors. Transdermal estradiol, delivered by patch, gel, or cream, does not appear to raise the risk of blood clots or stroke to the same degree, and several large studies have found no significant increase at standard doses [7, 8].

In 2022, the Menopause Society updated its position statement to reflect this evidence, concluding that for healthy symptomatic women under 60 or within ten years of menopause, the benefits of hormone therapy generally outweigh the risks, and that there is no fixed age or duration at which therapy must stop [9].

What “Bioidentical” Means for Safety

Bioidentical hormones are molecularly identical to the hormones your body produces: estradiol rather than conjugated equine estrogens, and micronized progesterone rather than a synthetic progestin. Both are available as FDA-approved commercial products as well as in compounded forms. The evidence discussed above suggests that transdermal estradiol combined with micronized progesterone carries a lower clotting risk and a more favorable breast profile than the older oral synthetic combination. That does not make bioidentical hormone therapy risk-free, and “bioidentical” is not a guarantee of safety on its own; it is a description of the molecule. The safest hormone therapy is the one that is individualized, uses the appropriate route and the lowest effective dose, and is monitored over time.

Who Should Not Use Hormone Therapy, and Who Needs a Closer Look

A short list of conditions rules out systemic hormone therapy outright. A longer list of conditions raises the risk enough that a standard prescription is not appropriate, but does not close the door; in these situations, the choice of hormone, dose, and route matters a great deal, and the decision is made together with the specialist who manages that condition.

Systemic hormone therapy should not be started if you have:

• Unexplained vaginal bleeding that has not been evaluated
• An active estrogen-sensitive cancer, or one currently being treated
• A blood clot, heart attack, or stroke that is recent or still being treated
• Active liver disease
• A current pregnancy

After an Estrogen-Sensitive Cancer

A history of breast cancer or another estrogen-sensitive cancer has traditionally been treated as an absolute barrier to systemic hormone therapy, and for many women it still is. Current guidelines do not recommend systemic estrogen for most breast cancer survivors, and non-hormonal options for hot flashes, such as fezolinetant, certain antidepressants, and gabapentin, are usually tried first [9, 10].

That said, “history of cancer” covers a wide range of situations. A woman with an estrogen-receptor-negative tumor treated many years ago is in a different position from a woman finishing anti-estrogen therapy for a receptor-positive cancer. Factors that influence the discussion include the tumor’s receptor status, the stage and time since treatment, current risk of recurrence, whether she is taking tamoxifen or an aromatase inhibitor, and how severely symptoms are affecting her quality of life after non-hormonal options have been tried. For selected women, a low-dose transdermal regimen may be considered after a shared decision with her oncologist, with clear documentation of the risks and close follow-up. Low-dose vaginal estrogen, which is absorbed minimally into the bloodstream, is considered reasonable for most survivors with genitourinary symptoms, again with the oncologist’s agreement, and vaginal DHEA is another option in this group [11].

After a Blood Clot

The concern with hormone therapy and clotting is specific to oral estrogen, which passes through the liver and raises clotting factors. Transdermal estradiol, delivered through the skin by patch, gel, or cream, largely bypasses this effect, and observational studies have not found a meaningful increase in clot risk with transdermal estradiol at standard doses, even in women with prior clots or inherited clotting disorders. Micronized progesterone likewise appears neutral for clotting, unlike some synthetic progestins [7, 8, 13].

For a woman with a history of deep vein thrombosis or pulmonary embolism, oral estrogen remains off the table. A transdermal regimen may be considered once the acute event has been fully treated, generally not sooner than [six to twelve months] after the clot, and after review with her hematologist. The discussion weighs whether the clot was provoked (by surgery, immobility, or pregnancy, for example) or unprovoked, whether a clotting disorder was identified, whether she remains on anticoagulation, and how significant her symptoms are. Women on long-term anticoagulation are sometimes the most straightforward candidates in this group, because the anticoagulant addresses the risk directly [13].

After a Heart Attack or Stroke

Hormone therapy is not started in the months following a heart attack or stroke, and it is not used to prevent cardiovascular disease [9]. Beyond the acute period, generally at least [twelve months] after the event with stable cardiovascular status, the question becomes individual. Oral estrogen is avoided because of its effects on clotting and triglycerides. Low-dose transdermal estradiol with micronized progesterone has a more favorable cardiovascular profile, and for a woman with severe symptoms that have not responded to other treatments, it may be considered in collaboration with her cardiologist, who can assess her current risk, the stability of her disease, and whether her blood pressure, lipids, and other risk factors are well controlled. For many women in this category, the safer path is non-hormonal symptom management plus local vaginal estrogen; for some, a carefully chosen low-dose transdermal regimen is reasonable.

Other Situations That Shape the Prescription

A family history of breast cancer, migraines with aura, high blood pressure, obesity, smoking, diabetes, or a history of gallbladder disease do not rule out hormone therapy, but each pushes the choice toward a transdermal route, the lowest effective dose, and micronized progesterone rather than a synthetic progestin. Women with a uterus who take estrogen need progesterone to protect the uterine lining; women without a uterus generally do not.

The common thread in every higher-risk situation is the same: the route and dose are chosen deliberately, the risks are discussed openly, the specialist who manages the underlying condition is part of the decision, and follow-up is closer than it would be for a lower-risk patient.

What Monitoring Looks Like

Safe hormone therapy is an ongoing relationship, not a one-time prescription. Before starting, a thorough history, a review of your cancer screening, and baseline labs establish that therapy is appropriate. After starting, follow-up visits and labs confirm that your levels are in the intended range and that the dose is the lowest one that controls your symptoms. Breast and cervical screening continue on schedule, and any new bleeding after menopause is evaluated promptly. The decision to continue is revisited periodically based on your symptoms, your health, and your preferences.

The Bottom Line

For a healthy woman in her forties or fifties with symptoms that affect her life, the weight of current evidence is that hormone therapy is a reasonable and often beneficial choice, and that fear rooted in a 2002 headline has kept many women from relief they could have had. For a woman with certain health histories, it may not be the right choice, and there are other effective options. The way to know which describes you is a careful conversation with a provider who knows the current evidence and your full history. Testosterone has its own safety profile [12], covered in our article on testosterone therapy for women, and our guide to the stages of menopause explains how timing affects the decision.

Ready to Find Out Where You Stand?

If you have been putting off the hormone conversation because of what you heard years ago, it may be time to revisit it with current information. Learn more about bioidentical hormone therapy at ForwardFlow Health or schedule a consultation to talk with our provider.

This article is for general education and is not a substitute for individualized medical advice. Talk with a licensed provider about your own health history before starting or stopping any hormone therapy.

References

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

2. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.

3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.

4. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380.

5. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221-1231.

6. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111.

7. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.

8. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.

9. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

10. The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.

11. The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.

12. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.

13. Morris G, Talaulikar V. Hormone replacement therapy in women with history of thrombosis or a thrombophilia. Post Reprod Health. 2023;29(1):33-41.